ArticleEmerging infectious diseases2005
Hybrid Vibrio vulnificus.
Article in Emerging infectious diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Emergence, climate-driven expansion, and diversification of a EuropeanEmerging microbes & infections · 2026Article
- Genomic Insight into Zoonotic and EnvironmentalMicroorganisms · 2024Article
- Virulent properties and genomic diversity ofMicrobiology spectrum · 2024Article
- A case report ofHeliyon · 2023Article
- What Whole Genome Sequencing Has Told Us About Pathogenic Vibrios.Advances in experimental medicine and biology · 2023Review
- Vibrio Infections and the Twenty-First Century.Advances in experimental medicine and biology · 2023Article
- Identification of potential pathogenic targets and survival strategies ofFrontiers in cellular and infection microbiology · 2023Article
- Article
- Identification and whole-genome sequencing analysis of Vibrio vulnificus strains causing pearl gentian grouper disease in China.BMC microbiology · 2022Article
- Sewage Promotes Vibrio vulnificus Growth and Alters Gene Transcription in Vibrio vulnificus CMCP6.Microbiology spectrum · 2022Article
- Ecological diversification reveals routes of pathogen emergence in endemicProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Method for Specific Identification of the Emerging Zoonotic Pathogen Vibrio vulnificus Lineage 3 (Formerly Biotype 3).Journal of clinical microbiology · 2021Article
- Molecular Detection and Distribution of Six Medically ImportantFrontiers in microbiology · 2021Article
- Phylogeography of the marine pathogen, Vibrio vulnificus, revealed the ancestral scenarios of its evolution.MicrobiologyOpen · 2020Article
- Alterations of the human skin microbiome after ocean water exposure.Marine pollution bulletin · 2019Article
- Pandemic fluoroquinolone resistantProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Article
- Uncovering the geographical and host impacts on the classification ofEvolutionary applications · 2018Article
- Occurrence of clinical genotypeJournal of food science and technology · 2017Article
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The recent emergence of the human-pathogenic Vibrio vulnificus in Israel was investigated by using multilocus genotype data and modern molecular evolutionary analysis tools. We show that this pathogen is a hybrid organism that evolved by the hybridization of the genomes from 2 distinct and independent populations. These findings provide clear evidence of how hybridization between 2 existing and nonpathogenic forms has apparently led to the emergence of an epidemic infectious disease caused by this pathogenic variant. This novel observation shows yet another way in which epidemic organisms arise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.